Alpha Cognition is trading 7.18% up now at $9.25 after reporting second-quarter results on August 13, 2026, with ZUNVEYL net product revenue rising approximately 71% sequentially to $6.0 million.
- Total revenue reached $6.1 million versus $1.7 million a year earlier.
- Demand was supported by broader prescriber adoption and increased nursing-home ordering.
- Improved results provide a clear catalyst for the gain.